We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Partial Oral Treatment of Endocarditis (POET)

This study is currently recruiting participants.
Verified July 2017 by Kasper Iversen, Rigshospitalet, Denmark
Sponsor:
ClinicalTrials.gov Identifier:
NCT01375257
First Posted: June 17, 2011
Last Update Posted: July 24, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
Kasper Iversen, Rigshospitalet, Denmark
June 13, 2011
June 17, 2011
July 24, 2017
June 2011
July 2017   (Final data collection date for primary outcome measure)
The primary endpoint is a composite endpoint including all cause mortality, unplanned cardiac surgery, embolic events and relapse of positive blood cultures with the primary pathogen [ Time Frame: Approximately 7 months. From randomisation until 6 months after end of study medication ]
Same as current
Complete list of historical versions of study NCT01375257 on ClinicalTrials.gov Archive Site
  • Quality of life [ Time Frame: Approximately 7 months. From randomisation until 6 months after end of study medication ]
    QOL performed during the study and after completion of the study
  • Cost of treatment [ Time Frame: Approximately 7 months. From randomisation until 6 months after end of study medication ]
  • Duration of antibiotic therapy [ Time Frame: Approximately 7 months. From randomisation until 6 months after end of study medication ]
  • Complications related to intravenous catheter [ Time Frame: 6 weeks ]
  • Quality of life [ Time Frame: Approximately 7 months. From randomisation until 6 months after end of study medication ]
    QOL performed during the study and after completion of the study
  • Cost of treatment [ Time Frame: Approximately 7 months. From randomisation until 6 months after end of study medication ]
  • Duration of antibiotic therapy [ Time Frame: 4 weeks ]
  • Number of cerebral infarcts [ Time Frame: Approximately 7 months. From randomisation until 6 months after end of study medication ]
  • Complications related to intravenous catheter [ Time Frame: 4 weeks ]
Not Provided
Not Provided
 
Partial Oral Treatment of Endocarditis
Partial Oral Treatment of Endocarditis

Background Current management of infective endocarditis include admission and treatment with parenteral antibiotics for 4 weeks - 6 weeks. Resource demands and psychological issues of present management strategy make it highly relevant to seek for alternative more lenient alternatives. Experiences with oral treatment are only sporadically described, but observational data suggest that oral treatment could be a feasible option. The investigators have in 2010 treated 12 endocarditis patients with partial oral antibiotics with a 100% success rate.

Study design The POET study is a Danish multicenter, prospective, randomized, open label study. The primary aim is to show non-inferiority of partial oral treatment with antibiotics of endocarditis compared to full parenteral treatment. Stable patients (n=400) with streptococci, staphylococci or enterococci infecting the mitral valve or the aortic valve will be included. After a minimum of 10 days of parenteral treatment, patients will be randomized to oral therapy or parenteral therapy. Special recommendations for oral treatment have been developed based on expected minimal inhibitory concentrations and pharmacokinetic calculations. Patients will be followed for 6 months after completion of antibiotic therapy. The primary endpoint is a composition of all cause mortality, unplanned cardiac surgery, embolic events and relapse of positive blood cultures with the primary pathogen.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Endocarditis
  • Drug: Oral treatment with antibiotics for endocarditis
  • Drug: Guideline treatment with parenteral antibiotics
  • Active Comparator: Guideline treatment with parenteral antibiotics
    Guideline treatment with parenteral antibiotics
    Intervention: Drug: Guideline treatment with parenteral antibiotics
  • Experimental: Oral treatment with antibiotics
    Oral treatment with antibiotics based on resistens pattern
    Intervention: Drug: Oral treatment with antibiotics for endocarditis
Iversen K, Høst N, Bruun NE, Elming H, Pump B, Christensen JJ, Gill S, Rosenvinge F, Wiggers H, Fuursted K, Holst-Hansen C, Korup E, Schønheyder HC, Hassager C, Høfsten D, Larsen JH, Moser C, Ihlemann N, Bundgaard H. Partial oral treatment of endocarditis. Am Heart J. 2013 Feb;165(2):116-22. doi: 10.1016/j.ahj.2012.11.006. Epub 2013 Jan 3.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
400
Not Provided
July 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Left-sided endocarditis based on the Duke criteria
  • Infected with one of the following microorganisms:

    • Streptococci
    • Enterococcus faecalis
    • Staphylococcus aureus
    • Coagulase-negative staphylococci.
  • ≥ 18 years
  • At least 10 days of appropriate parenteral antibiotic treatment overall, and at least 1 week of appropriate parenteral treatment after valve surgery
  • Afebrile (T < 38.0) > 2 days
  • Decreasing infection parameters (CRP dropped to less than 25% of peak value or < 20 mg/l, and white blood cell count < 15 x 109/l) during antibiotic treatment
  • No sign of abscess formation by echocardiography
  • Transthoracic and transoesophageal echocardiography performed within 48 hours prior to randomization

Exclusion Criteria:

  • Body mass index > 40
  • Concomitant infection requiring intravenous antibiotic therapy
  • Inability to give informed consent to participation
  • Suspicion of reduced absorption of oral treatment due to abdominal disorder
  • Reduced compliance
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact: Kasper Iversen, MD 0045 35459863 kasper.iversen@dadlnet.dk
Contact: Henning Bundgaard 0045 35450512
Denmark
 
 
NCT01375257
Endocarditis-DK
Yes
Not Provided
Not Provided
Kasper Iversen, Rigshospitalet, Denmark
Rigshospitalet, Denmark
Not Provided
Not Provided
Rigshospitalet, Denmark
July 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP